Correction to: Astragaloside IV mitigates mitochondrial damage and neurological symptoms in rats with cervical spondylotic myelopathy by inhibiting IL‑17/TRAF6/NF‑κB pathway

Correction to: Naunyn-Schmiedeberg's Archives of Pharmacology

The original version of this article unfortunately contained a mistake.

The Figure 1 in the last version is incorrect.

Old Fig. 1:

figure a

Correct Fig. 1:

figure b

Section 3.4 in the last version had an incorrect sentence.

Furthermore, OE-TRAF6 transfection deceased the inhibitory impact of AS-IV on TRAF6/NF-κB pathway, further reducing IL-17, TRAF6, p-NF-κB/NF-κB, and p-IκB/IκB levels (Fig. 4O-S).

Furthermore, OE-TRAF6 transfection deceased the inhibitory impact of AS-IV on TRAF6/NF-κB pathway, increasing IL-17, TRAF6, p-NF-κB/NF-κB, and p-IκB/IκB levels (Fig. 4O-S).

The original article has been corrected.

Comments (0)

No login
gif